These results suggest that the ALDH1A1 isozyme is an important contributor to therapy resistance in breast cancer cells, not only to cyclophosphamide chemotherapy (as previously reported [13,38]), but also to other classes of chemotherapy and radiotherapy. Here, ALDH1A1 is linked to breast carcinoma.